Industry News
Pharmaceutical Industry News
AbbVie retook the top spot from…
AbbVie retook the top spot from rival J&J and its immunology drug Tremfya in July’s top TV drug ad spending rankings.
A Promising Heart Drug Fails, Challenging a Long-Held Theory of Disease
The drug targeted inflammation, and its shocking failure has experts questioning whether inflammation really does cause heart disease.
The partnership marks Basuch +…
The partnership marks Basuch + Lomb's foray into the digital and AI healthcare space.
In a remarkable turnaround,…
In a remarkable turnaround, Replimune has reversed the fortune of its melanoma therapy, winning FDA approval after two prior rejections and agency leadership shakeups.
The company and the National…
The company and the National Psoriasis Foundation will celebrate the second annual Generalized Pustular Psoriasis Awareness day on August 13.
The new platform bolsters Inizio…
The new platform bolsters Inizio Engage's medical information capabilities with expanded global infrastructure and AI-enabled innovation.
Takeda’s first-in-class orexin…
Takeda's first-in-class orexin treatment won an FDA nod for narcolepsy. Daiichi Sankyo faced investor pushback after admitting to an accounting error. Astellas booked a new quarterly revenue record. And more.
Life sciences leaders are…
Life sciences leaders are rethinking patient support as AI, connected data and trust reshape engagement.
After coming up short with two…
After coming up short with two OX2R agonists, Takeda has scored with oveporexton, gaining FDA approval for the first-in-class drug as a treatment for adults with narcolepsy type 1. Orzeyful, as it will be known
In his first earnings call just…
In his first earnings call just days after becoming Sarepta Therapeutics' CEO, Michael Severino recognized that the rare disease drugmaker faces multiple upcoming milestones that will clarify its growth trajectory.
A New Plan for Closer U.S.-Israel Military Cooperation, and the First mRNA Flu Vaccine
Plus, what happens when you have an A.I. boss.
Galderma Laboratories has landed a…
Galderma Laboratories has landed a blow on Sanofi in its multi-case advertising row, driving the French drugmaker to change or drop certain claims about its blockbuster medicine Dupixent.
F.D.A. Approves Moderna’s mRNA Flu Vaccine
The agency had initially refused to even review the application but reversed course after a public outcry.
Despite a major curveball thrown…
Despite a major curveball thrown by the FDA earlier this year, Moderna has managed to strike true with a U.S. approval for its mRNA-based influenza vaccine.
Two and a half years into his…
Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to align the business with “current business realities.”
ViiV Healthcare is urging people…
ViiV Healthcare is urging people to think about how today’s HIV prevention and treatment choices could shape their future. Its new “Do It For Future You” campaign spotlights long-acting options through a digital push that
AstraZeneca and CSPC…
AstraZeneca and CSPC Pharmaceutical are strengthening their partnership by establishing a new biologics manufacturing joint venture in China.
Alcon’s back-to-school campaign…
Alcon's back-to-school campaign for its Precision contact lenses looks to help eye doctors better reach their Gen Z patients.
Gilead’s HIV prevention business…
Gilead’s HIV prevention business reached a milestone, exceeding $1 billion in quarterly sales for the first time, as highlighted by CEO Daniel O’Day. But one group of analysts is raising doubts about the long-term growth
Novo’s Wegovy pill thesis…
Novo’s Wegovy pill thesis continues to bear out in 2026, as the oral obesity med keeps impressive sales apace while sparing pre-existing prescriptions tied to the company’s injectable GLP-1.